1. Home
  2. ALKS vs TVTX Comparison

ALKS vs TVTX Comparison

Compare ALKS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkermes plc

ALKS

Alkermes plc

HOLD

Current Price

$38.99

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$44.59

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKS
TVTX
Founded
1987
N/A
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
ALKS
TVTX
Price
$38.99
$44.59
Analyst Decision
Buy
Strong Buy
Analyst Count
14
13
Target Price
$43.43
$40.62
AVG Volume (30 Days)
1.7M
2.7M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.89
EPS
N/A
N/A
Revenue
$1,475,899,000.00
N/A
Revenue This Year
$24.26
$44.76
Revenue Next Year
$4.47
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.17
$13.88
52 Week High
$38.45
$48.61

Technical Indicators

Market Signals
Indicator
ALKS
TVTX
Relative Strength Index (RSI) 71.82 65.78
Support Level $27.65 $26.97
Resistance Level N/A $48.61
Average True Range (ATR) 1.29 2.26
MACD 0.34 -0.26
Stochastic Oscillator 87.89 53.95

Price Performance

Historical Comparison
ALKS
TVTX

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: